Table 2.
Percent neutralization of different virus strains by SHIVIG in TZM-bl cell-based assay
| Virus | Clade | Tier | SHIVIG | bPositive control |
|---|---|---|---|---|
| KNH1088.ec5 |
A |
2 |
0 |
83 |
| SF162 PV |
B |
1 |
94 |
100 |
| BaL.ec1 |
B |
1 |
92 |
99 |
| GS015.ec12 |
C |
1 |
74 |
95 |
| GS 014 IMC |
C |
2 |
0 |
82 |
| E0836M4.ec3 |
D |
2 |
0 |
80 |
| CM235.ec5 |
AE |
2 |
66 |
100 |
| GS 020 IMC |
AE |
2 |
0 |
38 |
| 55815.ec3 |
AG |
2 |
0 |
75 |
| SHIV-2873Nip | C | 2 | a58 | c56 |
SHIVIG was tested at 0.5 mg/ml, except where noted. aNeutralization obtained with 1 mg/ml of SHIVIG. bAn HIV-positive serum pool was used as positive control, except as indicated. cBnmAb VRC01 (50 μg/ml) was used as positive control. IMC, infectious molecular clone. All neutralization assays were performed at least in duplicate.